Details for Patent: 9,844,545

Title:	Methylphenidate extended release chewable tablet
Abstract:	An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
Inventor(s):	Tu; Yu-Hsing (West Windsor, NJ), Perumal; Ashok (Monmouth Junction, NJ), Kathala; Kalyan (Monmouth Junction, NJ)
Assignee:	TRIS PHARMA, INC. (Monmouth Junction, NJ)
Filing Date:	Apr 19, 2017
Application Number:	15/491,547
Claims:	1. An extended release racemic methylphenidate chewable tablet, wherein the chewable tablet is a solid dispersion comprising: (a) a sustained release, racemic methylphenidate component comprising a water-insoluble, water-permeable, pH-independent barrier coated, racemic methylphenidate-cation exchange resin complex which comprises: (i) a racemic methylphenidate-cation exchange resin complex comprising racemic methylphenidate and a pharmaceutically acceptable cation ion exchange resin, wherein the racemic methylphenidate is bound to the pharmaceutically acceptable cation exchange resin; (ii) a water-insoluble, water-permeable, pH-independent, barrier coating comprising cellulose acetate and a plasticizer; wherein the barrier coating provides a sustained release profile to the racemic methylphenidate as defined in (a); and wherein about 50% w/w to about 90% w/w of total racemic methylphenidate in the chewable tablet is provided by the sustained release component; and (b) an immediate racemic methylphenidate component comprising racemic methylphenidate-cation exchange resin complex which provides a release of the racemic methylphenidate in less than about 30 minutes as determined in an in vitro dissolution assay, wherein the methylphenidate-cation exchange resin complex comprises racemic methylphenidate bound to a pharmaceutically acceptable cation exchange resin; wherein the chewable tablet is capable of being divided and providing tablet portions which retain a therapeutically effective extended release profile, and a pharmacokinetic profile in which the racemic methylphenidate has at least one of: a geometric mean for area under the curve (AUC).sub.0-.infin. of about 110 ng-hr/mL to about 140 ng-hr/mL or a geometric mean C.sub.max of about 10 ng/mL to about 15 ng/mL, under fasted conditions in adults following a single oral administration of the chewable tablet which has a total amount of racemic methylphenidate which is the equivalent of 40 mg racemic methylphenidate HCl. 2. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the plasticizer is selected from propylene glycol, polyethylene glycol, dibutyl sebacate, propylene glycol, polyethylene glycol, polyvinyl alcohol, triethyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, tributyl citrate, triacetin, 2-pyrrolidone, or mixtures thereof. 3. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the plasticizer comprises triethyl citrate. 4. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the plasticizer comprises polyethylene glycol. 5. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the barrier coating is applied as a solvent based suspension. 6. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the barrier coating is cured. 7. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the water-insoluble, water-permeable, pH-independent polymer is present in the barrier coat an amount of about 70% to about 90% w/w, based on the weight of the final barrier coating layer. 8. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the barrier coating is about 15% by weight to about 65% by weight of the methylphenidate-cation ion exchange resin complex defined in (i) as determined prior to the racemic methylphenidate-cation exchange resin complex being coated with the barrier coating of (ii), wherein the racemic methylphenidate-cation exchange resin is optionally in a matrix which further comprises at least one polymer or copolymer. 9. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the barrier coat is present in an amount of about 20% w/w to about 50% w/w % based on the weight of the racemic methylphenidate-cation exchange resin complex defined in (i) as determined prior to the racemic methylphenidate-cation exchange resin complex being coated with the barrier coating of (ii), wherein the racemic methylphenidate-cation exchange resin is optionally in a matrix which further comprises at least one polymer or copolymer. 10. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the barrier coat is present in an amount of about 20% w/w to about 35% w/w % based on the weight of the racemic methylphenidate-cation exchange resin complex defined in (i) as determined prior to the racemic methylphenidate-cation exchange resin complex being coated with the barrier coating of (ii), wherein the racemic methylphenidate-cation exchange resin is optionally in a matrix which further comprises at least one polymer or copolymer. 11. The extended release racemic methylphenidate chewable tablet according to claim 10, wherein the immediate release component comprises about 20% w/w to about 40% w/w of the total racemic methylphenidate in the chewable tablet. 12. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the barrier coated methylphenidate-cation exchange resin complex as defined in (ii) are particulates having a mean particle size in the range of about 100 microns to about 450 microns. 13. The extended release racemic methylphenidate chewable tablet according to claim 12, wherein the barrier coated methylphenidate-cation exchange resin complex as defined in (ii) are particulates having a mean particle size in the range of about 150 microns to about 300 microns. 14. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the sustained release methylphenidate component provides about 60% w/w to about 80% w/w of the methylphenidate in the chewable tablet, based on the total amount of methylphenidate in the chewable tablet. 15. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the tablet has a hardness in the range of about 8 kp to about 23 kp. 16. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the in vitro dissolution assay is performed placing the tablet in 900 mL 0.4 M potassium phosphate buffer with 37.degree. C..+-.5.degree. C. with a USP paddle speed of 75 rpm. 17. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the tablet has a pharmacokinetic profile for racemic methylphenidate comprising a single mean plasma concentration peak which is about 4 hours to about 5.25 hours under fasted conditions. 18. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein said tablet comprises the equivalent of 40 mg racemic methylphenidate HCl. 19. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein said tablet comprises the equivalent of 20 mg racemic methylphenidate HCl. 20. A method for treating a patient who has been diagnosed with attention deficit hyperactivity disorder, postural orthostatic tachycardia syndrome, or narcolepsy, said method comprising dosing said patient with an effective amount of a methylphenidate extended release chewable tablet according to claim 1. 21. The method according to claim 20, wherein said patient has attention deficit hyperactivity disorder. 22. The method according to claim 20, wherein the patient swallows the tablet intact. 23. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the methylphenidate plasma concentration, as determined under fasting conditions following a single oral administration of said chewable tablet at a dose equivalent to 40 mg racemic methylphenidate HCl in adults under fasting conditions, has the fasting plasma concentration curve of FIG. 1 from about 0 to about 8 hours. 24. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the pharmacokinetic profile for the methylphenidate further comprises an AUC0-3 which is bioequivalent to about 18 ng-hr/mL. 25. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the plasticizer is present in an amount of about 2.5% w/w to about 20% w/w of the barrier coating. 26. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the plasticizer is present in an amount of 2.5% w/w to about 15% w/w of the barrier coating. 27. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the barrier coat has an elongation factor of at least about 150% to about 400% as measured by a texture analyzer. 28. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein pharmacokinetic profile for methylphenidate further comprises one or more of an AUC0-3 of the fasting or fed plasma concentration curve of FIG. 1 or an AUC0-4 of the fasting or fed plasma concentration curve of FIG. 1. 29. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the barrier coating is about 10% by weight to about 40% by weight of the methylphenidate-cation ion exchange resin complex defined in (i) as determined prior to the racemic methylphenidate-cation exchange resin complex being coated with the barrier coating of (ii), wherein the racemic methylphenidate-cation exchange resin is optionally in a matrix which further comprises at least one polymer or copolymer. 30. The extended release racemic methylphenidate chewable tablet according to claim 29, wherein the racemic methylphenidate-cation ion exchange resin complex defined in (i) is in a matrix, wherein at least one polymer or copolymer is hydrophilic.